Aventis has announced the signing of a commercial research, option and license agreement with Vivalis in the field of avian stem cells.
The two companies will combine the ALVAC canarypox virus platform of Aventis Pasteur, the vaccines business of Aventis, and Vivalis’ proprietary avian stem cell platform to enable Aventis Pasteur to improve the large-scale production of several ALVAC vaccine candidates.
These vaccine candidates are in the fields of HIV and cancer.
In addition, an option has been signed allowing Aventis Pasteur to use Vivalis stem cell lines for the production of another major virus vaccine.
“The Vivalis avian stem cell technology, now at an early stage of development, is interesting to Aventis Pasteur as a potential means to scale-up production of a range of vaccine candidates,” commented Jeffrey Almond, senior vice president, Global Research and External Research & Development at Aventis Pasteur.
“Several ALVAC candidate vaccines are now moving forward in clinical development and we need to consider novel large-scale production methods.”
“Aventis Pasteur is one of the world’s largest vaccine producers. Being able to collaborate with such an established player in this field provides an important further endorsement of our stem cell line technology in the vaccine industry,” said Franck Grimaud, Vivalis CEO, and Alain Munoz, Vivalis board member.
While the commercial terms are confidential, the agreement entails upfront payment, milestones payment and royalties for Vivalis.